Status:
ACTIVE_NOT_RECRUITING
Follow up Study of Crocin on Cardiac Function Protection in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy Based on Color Doppler Ultrasound Combined With Myocardial Zymogram
Lead Sponsor:
Mei Zhang
Conditions:
Breast Cancer
Eligibility:
FEMALE
20-80 years
Brief Summary
Foreign data show that: 1807 tumor patients were followed up for 7 years, 33% of them died of heart disease and 51% of them died of the tumor itself. In China, the number of cancer patients undergoing...
Detailed Description
At present, the commonly used anthracycline antineoplastic drugs in clinic include daunorubicin, doxorubicin, epirubicin, pirarubicin, idabicin, pentarubicin and mitoxantrone, among which doxorubicin ...
Eligibility Criteria
Inclusion
- Female patients with breast cancer aged ≥ 20 years and ≤ 80 years, with informed consent and meeting the treatment standard of neoadjuvant chemotherapy scheme.
- Patients who plan to receive neoadjuvant chemotherapy based on anthracycline drugs (such as erythromycin, doxorubicin, epirubicin, pyranomycin, idabicin, pentorubicin, and mitoxantrone).
- No treatment for breast cancer before enrollment, such as chemotherapy, targeted therapy and endocrine therapy.
- All patients underwent coarse needle biopsy of breast tumors (axillary lymph node biopsy is required for suspected axillary lymph node metastasis) to determine the status of ER, PR, HER-2, and Ki-67.
- All patients have normal lung function, liver and kidney function.
Exclusion
- Cases that do not cooperate and are unwilling to sign informed consent forms.
- Antitumor therapy, hormone replacement therapy and other breast cancer related treatments were performed before enrollment.
- Merge any other malignant tumors.
- Patients with poor image quality in echocardiography.
- Continuous atrial fibrillation and severe arrhythmia affect ultrasound data collection and analysis.
- Patients with active infections, a history of HIV, or chronic hepatitis B or C.
- Patients with abnormal lung function or liver and kidney function.
- Patients with hemorrhagic diseases.
- Patients taking other heart protection traditional Chinese patent medicines and simple preparations.
- Participated in other clinical researchers in the past 3 months.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06187818
Start Date
September 1 2023
End Date
September 1 2026
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital in Shandong Province)
Jinan, Shandong, China, 250013